Skip to main content
PROK
NASDAQ Life Sciences

ProKidney 10-Q: $141.9M Cash Won't Fund 12 Months, Going Concern Doubt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.15
Mkt Cap
$347.727M
52W Low
$0.87
52W High
$2.88
52W Position info
32% above low
Off High info
60% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PROK sits 32% above its 52-week low of $0.87.

Summary

ProKidney's Q3 10-Q shows $141.9M of cash and securities, a formal going-concern warning, and a nine-month operating burn of $120.7M, with a fresh $200M at-the-market program as the funding backstop.


Key Events · Earnings and Guidance · PROK

  • Going Concern Doubt Disclosed

    Management concluded that existing cash and marketable securities of $141,864,000 at September 30, 2026 will not fund obligations for the 12 months following the filing, and added a going-concern risk factor.

  • Cash Burn Accelerates

    Operating cash use was $120.7M for nine months versus $87.6M a year earlier; cash and equivalents fell to $81.4M from $108.5M at December 31, 2025.

  • R&D Spend Jumps on PROACT 1

    Q3 research and development expense rose to $40.8M from $26.8M, driving a net loss available to Class A holders of $35.6M for the quarter and $84.1M for nine months.

  • $200M ATM Is the Funding Backstop

    The October 29, 2026 Jefferies at-the-market agreement allows up to $200M of Class A stock sales; no shares have been sold under it, and the prior 2025 agreement terminates November 23, 2026.


Analysis · PROK · Life Sciences

ProKidney closed Q3 2026 with $141.9M in cash and marketable securities, and management now says that is not enough to fund obligations for the 12 months after this filing — a formal going-concern conclusion and a new risk factor. The burn is accelerating: operating cash use was $120.7M over nine months versus $87.6M a year earlier, and R&D jumped to $40.8M in Q3 from $26.8M as the Phase 3 PROACT 1 trial enrolls. The company's answer is the $200M Jefferies at-the-market program set up October 29, 2026, which is pure dilution if drawn. The offset is clinical: full enrollment in PROACT 1 is expected in Q1 2027 and the surrogate eGFR-slope topline in Q2 2027 — the data that would justify financing the company at all.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PROK was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.7M. The 52-week trading range was $0.87 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PROK - Latest Insights

PROK
Nov 12, 2026, 4:10 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.05 info
Change: -$0.105 (-9%) info
Market Cap: $315.978M info
PROK
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $1.05 info
Change: -$0.095 (-8%) info
Market Cap: $315.978M info
PROK
Oct 29, 2026, 4:46 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.46
Real-time Price: $1.05 info
Change: -$0.415 (-28%) info
Market Cap: $315.978M info
PROK
Aug 10, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.05 info
Change: -$0.595 (-36%) info
Market Cap: $315.978M info
PROK
Aug 10, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.05 info
Change: -$0.595 (-36%) info
Market Cap: $315.978M info